Mostrando 381 - 400 Resultados de 1,900 Para Buscar '"AstraZeneca"', tiempo de consulta: 0.14s Limitar resultados
  1. 381
    “…The aim of the study was to compare the safety profiles (prevalence of both local and systemic side effects) of COVID-19 vaccines (Pfizer–BioNTech, Moderna, Oxford–AstraZeneca) among healthcare workers (doctors, nurses, and pharmacists) administered with a first and a second dose of the vaccines. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  2. 382
    “…This study aims to compare the mean titers, duration, and efficacy of generating protective anti-RBD IgG antibody response among recipients of Pfizer/BioNTech, AstraZeneca, Sputnik V, Johnson & Johnson, Moderna, and Sinopharm COVID-19 vaccines. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  3. 383
    “…Data were collected using a structured checklist developed following an extensive literature review of the national and international standards for Pfizer-BioNTech and AstraZeneca COVID-19 vaccines. A scoring system for the overall vaccination process was developed. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  4. 384
    “…Pain at the injection site was the commonest among control (77 %). ChAdOx1 (AstraZeneca) had the highest incidence of side effects, mRNA1273 (Moderna) showed the lowest. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  5. 385
  6. 386
    “…By the end of March 2021, in Ceará State, a total of 313,328 elderly people had received at least one dose of vaccine (45% Oxford-AstraZeneca/Fiocruz and 55% CoronaVac-Sinovac/Butantan), and 159,970 had received two doses (83% CoronaVac-Sinovac/Butantan and 17% Oxford-AstraZeneca/Fiocruz). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  7. 387
  8. 388
    por Murgova, Snezhana, Balchev, Georgi
    Publicado 2022
    “…BACKGROUND: The aim of this report is to describe ocular side effects in patients who received one of the two COVID-19 vaccines – Astra Zeneca or Pfizer-Biontech and to contribute to the common understanding of the COVID-19 vaccination process. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  9. 389
    “…Cosgrove, PhD, Novavax: Advisor/Consultant|Novavax: Grant/Research Support|Novavax: Speaker Patrick Moore, MRCGP, AstraZeneca: Advisor/Consultant|AstraZeneca: Grant/Research Support|GSK: Advisor/Consultant|GSK: Grant/Research Support|Janssen: Advisor/Consultant|Janssen: Grant/Research Support|Medicago: Advisor/Consultant|Medicago: Grant/Research Support|Moderna, Inc.: Advisor/Consultant|Moderna, Inc.: Grant/Research Support|MSD: Advisor/Consultant|MSD: Grant/Research Support|Novavax: Advisor/Consultant|Novavax: Grant/Research Support|Sanofi: Advisor/Consultant|Sanofi: Grant/Research Support Philip Kalra, MD, Astellas: Advisor/Consultant|Astellas: Grant/Research Support|AstraZeneca: Advisor/Consultant|AstraZeneca: Grant/Research Support|Bayer: Advisor/Consultant|Bayer: Grant/Research Support|Evotec: Advisor/Consultant|Evotec: Grant/Research Support|Fresenius: Advisor/Consultant|Fresenius: Grant/Research Support|GSK: Advisor/Consultant|GSK: Grant/Research Support|Lilly: Advisor/Consultant|Lilly: Grant/Research Support|Otsuka: Advisor/Consultant|Otsuka: Grant/Research Support|Pfizer: Advisor/Consultant|Pfizer: Grant/Research Support|Pharmacosmos: Advisor/Consultant|Pharmacosmos: Grant/Research Support|Unicyte: Advisor/Consultant|Unicyte: Grant/Research Support|Vifor: Advisor/Consultant|Vifor: Grant/Research Support Paul Dargan, MBBS, Moderna, Inc.: Grant/Research Support Marta Boffito, MD, PhD, FRCP, AstraZeneca: Honoraria|ATEA: Advisor/Consultant|ATEA: Honoraria|Gilead: Advisor/Consultant|Gilead: Grant/Research Support|Gilead: Honoraria|GSK: Advisor/Consultant|GSK: Grant/Research Support|Moderna: Grant/Research Support|MSD: Advisor/Consultant|MSD: Grant/Research Support|MSD: Honoraria|Novavax: Grant/Research Support|Pfizer: Advisor/Consultant|Pfizer: Grant/Research Support|Roche: Advisor/Consultant|Roche: Grant/Research Support|Valneva: Grant/Research Support|ViiV: Advisor/Consultant|ViiV: Grant/Research Support Fiona Burns, PhD, Gilead Sciences Ltd.: Grant/Research Support|Gilead Sciences Ltd.: Speaker Fees Christopher J. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  10. 390
    Publicado 2009
    Libro
  11. 391
    “…Prof, Ablynx, Gilead, Regeneron, Roche, Abbott and MedImmune: Honoraria|Ablynx, Gilead, Regeneron, Roche, Abbott and MedImmune: principal investigator|Astra Zeneca, GSK, Pfizer Inc, Sanofi, MSD, Seqirus, Moderna, Novavax, Biofabri, and Janssen: Advisor/Consultant|Astra Zeneca, GSK, Pfizer Inc, Sanofi, MSD, Seqirus, Moderna, Novavax, Biofabri, and Janssen: Board Member|Astra Zeneca, GSK, Pfizer Inc, Sanofi, MSD, Seqirus, Moderna, Novavax, Biofabri, and Janssen: Honoraria|Astra Zeneca, GSK, Pfizer Inc, Sanofi, MSD, Seqirus, Moderna, Novavax, Biofabri, and Janssen: speaker and investigator Courtney Lambeth, BS, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA: employee|Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA: Stocks/Bonds Ziqiang Chen, PhD, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA: employee|Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA: Stocks/Bonds Jessie Lumley, MA, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA: employee|Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA: Stocks/Bonds David Johnson, MD, MPH, Sanofi: employee Marissa B. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  12. 392
    “…DISCLOSURES: Simon Pollett, MBBS, Astra Zeneca (Other Financial or Material Support, HJF, in support of USU IDCRP, funded under a CRADA to augment the conduct of an unrelated Phase III COVID-19 vaccine trial sponsored by AstraZeneca as part of USG response (unrelated work)) Ryan C. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  13. 393
    “…In March 2021 Germany limited the use of the Oxford-AstraZeneca COVID-19 vaccine to people 60 years of age and older due to concerns that it may be causing blood clots. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  14. 394
    “…Vaccine-induced immune thrombotic thrombocytopenia (VITT) (also termed thrombosis with thrombocytopenia syndrome or vaccine-induced thrombotic thrombocytopenia or vaccine-induced immune thrombocytopenia) is characterized by (i) venous or arterial thrombosis; (ii) mild-to-severe thrombocytopenia; (iii) positive antiplatelet factor 4 (PF4)–polyanion antibodies or anti-PF4–heparin antibodies detected by the HIT (heparin-induced thrombocytopenia) ELISA; (iv) occurring 5–30 days after ChAdOx1 nCoV-19 (AstraZeneca) or Ad26.COV2.S (Johnson & Johnson/Janssen) vaccination. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  15. 395
    “…With the rapid and massive vaccination campaign against coronavirus disease 2019 (COVID-19) taking place across the globe, there are increasing reports of thrombotic complications with various COVID-19 vaccines such as the Pfizer–BioNTech mRNA, Moderna mRNA, AstraZeneca Oxford (serum institute), and Johnson & Johnson/Janssen vaccines. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  16. 396
    “…Vaccine-induced immune thrombotic thrombocytopenia (VITT) with venous thrombosis is a rare complication of SARS-CoV-2 vaccination with ChAdOx1 (AstraZeneca) and AD26.COV2.S (Johnson & Johnson, New Brunswick, NJ, USA) associated with high mortality. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  17. 397
  18. 398
    “…Several cases of deep venous thrombosis in people who had recently received Vaxzevria (previously known as COVID-19 Vaccine AstraZeneca) have recently been reported, mainly presenting as cerebral vein/cerebral venous sinus thrombosis. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  19. 399
    “…This study aimed to assess the effect of one dose of COVID-19 vaccines (Pfizer-BioNTech, Manhattan, New York City, and Oxford-AstraZeneca, Cambridge, United Kingdom) among the Saudi population regarding symptom severity, hospital admission rate, and death. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  20. 400
Herramientas de búsqueda: RSS